Eric D. Tetzlaff, MHS, PA-C, DFAAPA

Department of Hematology/Oncology

This physician is not currently rated. Why?

Assistant Professor, Academic Clinician

Specialties

Treatment Philosophy

I chose to work at Fox Chase Cancer so that I could continue my career in oncology at an academic cancer center dedicated to providing quality care.

After graduating from Duke University's physician assistant program in 2004, I began my career in oncology as a physician assistant at the M.D. Anderson Cancer Center in Texas. I worked in the department of gastrointestinal medical oncology for four years, where I specialized in the treatment of gastroesophageal and hepatobiliary cancers. There, I had several manuscripts published in peer reviewed journals, and I presented original research at national oncology conferences.

At Fox Chase, I am focusing on the clinical care of patients with sarcomas and gastrointestinal cancers.

Clinical Locations

Primary Location
Fox Chase Cancer Center

Educational Background

MHS, PA Certificate, Duke University, Durham, NC, 2004
BA, Psychology, University of Vermont, Burlington, VT, 1998

Certifications

Pennsylvania Physician Assistant License, MA053353, 2008-Present
National Commission on Certification of Physician Assistants, 1065312, 2004-Present

Memberships

Association of Physician Assistants in Oncology (APAO)
- President, 2015-2016
- President Elect, 2014-2015
- Treasurer, 2013-2014
American Society of Clinical Oncology (ASCO)
- CME Subcommittee Member, June 2014-May2018
American Academy of Physician Assistants (AAPA)

Honors & Awards

Employee of the Month, Fox Chase Cancer Center, May 2013
2018 Publishing Award, American Academy of Physician Assistants, June 2018

Research Interests

Physician assistant workforce and utilization
Gastrointestinal cancers
Sarcoma

Selected Publications

Kosty MP, Acheson AK, Tetzlaff ED. Clinical oncology practice 2015: preparing for the future. Am Soc Clin Oncol Educ Book. 2015:e622-7. PubMed

Tetzlaff ED, Davey MP. Optimizing adherence to adjuvant imatinib in gastrointestinal stromal tumor. J Adv Pract Oncol. 2013 Jul;4(4):238-50. PubMed

Tetzlaff ED, Cheng JD, Ajani JA. Thromboembolism in gastrointestinal cancers. Gastrointest Cancer Res. 2008 Nov;2(6):267-72. PubMed

Tetzlaff ED, Cheng JD, Ajani JA. Review of docetaxel in the treatment of gastric cancer. Ther Clin Risk Manag. 2008 Oct;4(5):999-1007. PubMed

Tetzlaff ED, Cen P, Ajani JA. Emerging drugs in the treatment of advanced gastric cancer. Expert Opin Emerg Drugs. 2008 Mar;13(1):135-44. PubMed

Tetzlaff ED, Correa AM, Komaki R, Swisher SG, Maru D, Ross WA, Ajani JA. Significance of thromboembolic phenomena occurring before and during chemoradiotherapy for localized carcinoma of the esophagus and gastroesophageal junction. Dis Esophagus. 2008;21(7):575-81. PubMed

Tetzlaff E, Polansky M, Carr K, Mares J, Vu L. Physician assistants in oncology. J Oncol Pract. 2007 Sep;3(5):283. PubMed

Tetzlaff ED, Correa AM, Baker J, Ensor J, Ajani JA. The impact on survival of thromboembolic phenomena occurring before and during protocol chemotherapy in patients with advanced gastroesophageal adenocarcinoma. Cancer. 2007 May 15;109(10):1989-95. PubMed

Tetzlaff ED. Factors to consider before referring patients for major cancer surgery. JAAPA. 2007 Mar;20(3):21-2. PubMed

Tetzlaff ED, Faust J, Ajani JA. Longterm survival of a Western patient with metastatic gastric cancer treated with S-1 plus cisplatin. Gastric Cancer. 2006;9(2):140-3. PubMed

Tetzlaff ED, Hylton HM, DeMora L, et al: National Study of Burnout and Career Satisfaction Among Physician Assistants in Oncology: Implications for Team-Based Care. J Oncol Pract 14:e11-e22, 2018. Pubmed

Additional Publications

My NCBI

The following ratings and reviews are based on verified feedback collected from independently administered patient experience surveys. The ratings and comments submitted by patients reflect their own views and opinions. Patient identities are withheld to ensure confidentiality and privacy. Learn more about our Patient Experience Ratings.